NOVEMBER 03, 2022

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure.  A reduction in the risk of early death or respiratory failure at…

November 01, 2022

Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Fullscreen Mode

OCTOBER 26, 2022

Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business…

SEPTEMBER 15, 2022

Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral…

JULY 4, 2022

Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Phase 2-3 COVA study results expected in Q3 2022 Biophytis announces its CEO, Stanislas Veillet, PhD, has been hosting a presentation at the 4th Annual Longevity Therapeutics Summit in San Francisco. The Biophytis presentation entitled “Discussing the…

JUNE 30, 2022

Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…

BIO101 in development for the treatment of Sarcopenia

JUNE 27, 2022

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress Biophytis announced that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders). This…

JUNE 22, 2022

Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the…